{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-014062","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.793392+00:00","generated_at":"2026-06-03T01:44:11.883725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M","bullets":["BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.","Net loss improved to $10.7M from $39.2M in Q1 2023; cash position $209.8M as of March 31, 2024.","Raised FY 2024 BRIUMVI U.S. net revenue guidance to $270-290M (prior $220-260M) with Q2 target ~$65M.","Over 1,250 new BRIUMVI prescriptions in Q1; VA national formulary contract secured for anti-CD20 indications.","R&D spend $32.7M includes $8.8M license fee for azer-cel allogeneic CAR-T from Precision BioSciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-014062","json":"https://secwatch.observer/filing/0001437749-24-014062.json","markdown":"https://secwatch.observer/filing/0001437749-24-014062.md","text":"https://secwatch.observer/filing/0001437749-24-014062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/0001437749-24-014062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/tgtx20240430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:44:11.883725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79cae46adcbbc74e833011d6c964dff6130fc233","claim":"TG THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (raised).","evidence_excerpt":"On May 1, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924014062/0001437749-24-014062-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}